BiotechTube

Vigabatrin

ApprovedWithdrawn
0 views this week 0 watching💤 Quiet
Interest: 32/100
32
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
✓
Phase 3
5
Approved
Indication / Disease

Infantile Spasms

Conditions

Infantile Spasms

Trial Timeline

Jun 1, 2012 → —

NCT ID
NCT01413711

About Vigabatrin

Vigabatrin is a approved stage product being developed by Lundbeck for Infantile Spasms. The current trial status is withdrawn. This product is registered under clinical trial identifier NCT01413711. Target conditions include Infantile Spasms.

What happened to similar drugs?

2 of 6 similar drugs in Infantile Spasms were approved

Approved (2) Terminated (1) Active (4)
✅alglucosidase alfa + alglucosidase alfaSanofiApproved
✅Bacillus Clausii Multi ATB Resist + PlaceboSanofiApproved
🔄GWP42003-PJazz PharmaceuticalsPhase 3
🔄GWP42003-PJazz PharmaceuticalsPhase 3
🔄Cholic AcidsMirum PharmaceuticalsPhase 3
🔄Cipaglucosidase alfa + MiglustatAmicus TherapeuticsPhase 3

Hype Score Breakdown

Clinical
20
Activity
0
Company
12
Novelty
0
Community
0

Clinical Trials (2)

NCT IDPhaseStatus
NCT01413711ApprovedWithdrawn
NCT01266291ApprovedTerminated

Competing Products

16 competing products in Infantile Spasms

See all competitors
ProductCompanyStageHype Score
TSHA-101Taysha Gene TherapiesPhase 1/2
30
MAS825 + PlaceboNovartisPhase 2
39
alglucosidase alfa + alglucosidase alfaSanofiApproved
35
MyozymeSanofiPhase 2
35
Bacillus Clausii Multi ATB Resist + PlaceboSanofiApproved
43
RadiprodilUCBPhase 2
27
Larotrectinib (Vitrakvi, BAY2757556) + Standard of CareBayerPre-clinical
23
Sabril®LundbeckPre-clinical
23
NusinersenBiogenPre-clinical
23
GWP42003-PJazz PharmaceuticalsPhase 3
37
GWP42003-PJazz PharmaceuticalsPhase 3
37
Cerliponase AlfaBioMarin PharmaceuticalPre-clinical
27
Cholic AcidsMirum PharmaceuticalsPhase 3
37
Cipaglucosidase alfa + MiglustatAmicus TherapeuticsPhase 3
44
ATB200 + AT2221Amicus TherapeuticsPre-clinical
27
RP-L401Rocket PharmaceuticalsPhase 1
11